Metabolism of triazine anticancer agents.

[1]  B. Leyland-Jones,et al.  Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack? , 1986, Cancer treatment reports.

[2]  M. D’Incalci,et al.  Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine. , 1986, Cancer treatment reports.

[3]  J. Noordhoek,et al.  Absorption and metabolism of hexamethylmelamine and pentamethylmelamine in rat everted perfused gut segments: correlation with in‐vivo data , 1985, The Journal of pharmacy and pharmacology.

[4]  S. Garattini,et al.  Central side effects of pentamethylmelamine: biochemical and behavioural studies. , 1984, Biochemical pharmacology.

[5]  M. Broggini,et al.  Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma. , 1984, Biochemical pharmacology.

[6]  D. Ross,et al.  Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism. , 1984, Biochemical pharmacology.

[7]  J. Noordhoek,et al.  Rapid formation of N-hydroxymethylpentamethylmelamine by mitochondria from rat small intestinal epithelium. , 1983, Life sciences.

[8]  J. Noordhoek,et al.  Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism. , 1983, Cancer research.

[9]  M. Ames,et al.  Role of N-methylolpentamethylmelamine in the metabolic activation of hexamethylmelamine. , 1983, Cancer research.

[10]  Ames Mm,et al.  Parenteral formulation of hexamethylmelamine potentially suitable for use in man. , 1982 .

[11]  M. Broggini,et al.  Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine. , 1982, Biochemical pharmacology.

[12]  S. Garattini,et al.  Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers. , 1982, Cancer treatment reports.

[13]  J. Ajani,et al.  Phase I trial of pentamethylmelamine. , 1982, Cancer treatment reports.

[14]  M. Broggini,et al.  Routes of elimination of hexamethylmelamine and pentamethylmelamine in the rat. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  M. Broggini,et al.  Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice. , 1982, Cancer treatment reports.

[16]  C. Sessa,et al.  Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients. , 1981, European journal of cancer & clinical oncology.

[17]  M. Boyd,et al.  Phase I trial of pentamethylmelamine: a clinical and pharmacologic study. , 1981, Cancer treatment reports.

[18]  E. Garattini,et al.  In vivo and in vitro irreversible binding of hexamethylmelamine to liver and ovarian tumor macromolecules of mice. , 1981, Biochemical pharmacology.

[19]  C. Sessa,et al.  Cerebrospinal fluid levels of hexamethylmelamine and N-demethylated metabolites. , 1981, Cancer treatment reports.

[20]  R. Benjamin,et al.  Pharmacology of pentamethylmelamine in humans. , 1981, Cancer research.

[21]  S. Garattini,et al.  Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice. , 1981, Cancer treatment reports.

[22]  G. Goldenberg,et al.  Uptake and metabolism of hexamethylmelamine and pentamethylmelamine by L5178Y lymphoblasts in vitro. , 1980, Cancer research.

[23]  J. Kovach,et al.  Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine. , 1980, Cancer treatment reports.

[24]  A. Goldin,et al.  Comparative pharmacology of pentamethylmelamine and hexamethylmelamine in mice. , 1980, Cancer research.

[25]  S. Garattini,et al.  Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites. , 1980, British Journal of Cancer.

[26]  J. Neijt,et al.  Determination of hexamethylmelamine and metabolites in plasma or serum by gas-liquid chromatography with a nitrogen-sensitive detector. , 1980, Journal of chromatography.

[27]  G. Abel,et al.  In vitro cytotoxicity of the methylmelamines. , 1980, Chemico-biological interactions.

[28]  R. Fanelli,et al.  N-Hydroxymethylpentamethylmelamine, a major in vitro metabolite of hexamethylmelamine. , 1980, Life sciences.

[29]  Griffin Jp,et al.  Phase I study of pentamethylmelamine. , 1980 .

[30]  D. V. Van Echo,et al.  Phase I trial of pentamethylmelamine in patients with previously treated malignancies. , 1980, Cancer treatment reports.

[31]  J. Kovach,et al.  Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. , 1979, Cancer research.

[32]  M. D’Incalci,et al.  Gas chromatographic determination of hexamethylmelamine in mouse plasma. , 1979, Analytical biochemistry.

[33]  S. Garattini,et al.  Variable oral absorption of hexamethylmelamine in man. , 1978, Cancer treatment reports.

[34]  T. A. Connors,et al.  In vitro studies with hexamethylmelamine. , 1977, Biochemical pharmacology.

[35]  W. Ross,et al.  Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. , 1977, Chemico-biological interactions.

[36]  L. M. Lake,et al.  Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors. , 1975, Cancer research.

[37]  G. Bryan,et al.  Metabolism of hexamethylmelamine-ring-14C in rats and man. , 1974, Cancer research.

[38]  G. Bryan,et al.  N-demethylation of the antineoplastic agent hexamethylmelamine by rats and man. , 1973, Cancer research.

[39]  A. Demilo,et al.  Insect chemosterilants. VII. Oxidative degradation of hexamethylmelamine. , 1968, Journal of medicinal chemistry.

[40]  P. K. Smith,et al.  The distribution of radioactivity following administration of triethylenimino-s-triazine-C14 in tumor-bearing and control mice. , 1954, Cancer research.